Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers and gastrointestinal stromal tumors, including chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia, targeting malignant cells that express specific kinase abnormalities.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for oncology therapeutics across global markets.

Imatinib is a tyrosine kinase inhibitor used in hematologic malignancies and selected solid tumors.

- Chronic myeloid leukemia (CML): suppresses BCR‑ABL‑driven leukemic proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): blocks oncogenic signaling to achieve remission. - Gastrointestinal stromal tumor (GIST): inhibits KIT and PDGFRA mutations to control tumor growth.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower extremities. - Fatigue: generalized tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Muscle cramps: involuntary tightening of skeletal muscles. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells increasing infection risk. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Cardiac failure: reduced cardiac output presenting with dyspnea. - Severe hemorrhage: bleeding events requiring medical attention. - Interstitial lung disease: pulmonary inflammation causing cough and breathlessness. - Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly.

- Monitor blood counts: check complete blood count weekly during the first month. - Assess liver function: perform hepatic panel before treatment and periodically thereafter. - Evaluate cardiac status: baseline ECG and echocardiogram for patients with cardiac history. - Avoid use in pregnancy: drug is classified as Category D; discuss contraception. - Counsel on breastfeeding: contraindicated due to potential infant exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and toxicity. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations. - Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, cyclosporine): may require dose adjustments. - QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias. - Warfarin: enhanced anticoagulant effect may necessitate INR monitoring.